Endevica Bio
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Illinois, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1945 Techny Rd Ste 14, Northbrook, Illin...Phone Number
(573) 881-5080Website
www.endevicabio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Endevica Bio
Endevica Bio specializes in novel peptidomimetics designed to treat conditions such as cancer cachexia and obesity with minimal side effects. Their innovative drug pipeline includes TCMCB07, currently in a Phase 2 trial for cancer cachexia, as well as 710GO, a weight loss medication showing effectiveness in non-human primates. The company is dedicated to transforming patient outcomes through science-driven peptide therapeutics that overcome the limitations of traditional treatment modalities. Target clients include patients suffering from cancer-related weight loss and obesity.Explore more
Endevica Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Endevica Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Endevica Bio is spiking on competitors!
Earning: See what the market has to say on Endevica Bio recently announced quarterly report
Endevica Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Endevica Bio had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Endevica Bio has new funding data
Congratulate Masked Content for being promoted to Masked Content at Endevica Bio
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Endevica Bio launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Endevica Bio has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Endevica Bio as Masked Content
Find more new buyers
Compare Similar Companies to Endevica Bio
Compare insights from companies similar to Endevica Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Endevica Bio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Endevica Bio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Endevica Bio.
Endevica Bio financials insights
Gather financial insights about Endevica Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Series B
$10M
Endevica Bio Tech Stack
A closer look at the technologies used by Endevica Bio
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
New Hire
Executive Move
Executive Moves, New Hire
Endevica Bio News & Media
Endevica Announces Spinout of Kalohexis to Advance First- and Best-in-Class Therapeutics Harnessing the Melanocortin System to Treat Obesity and Metabolic Diseases
Kalohexis' lead programs include 710GO, an oral dual melanocortin-3 and-4 receptor (MC3R/MC4R) agonist, a next-generation general obesity treatment; and mifomelatide, a dual MC3R/MC4R antagonist to prevent and treat cachexia in advanced cancers 710GO has shown healthier, more durable...Endevica Bio Unveils Differentiated Mechanism for Durable Weight Loss in Obesity
NORTHBROOK, Ill., Oct. 2, 2025 /PRNewswire/ -- Endevica Bio, a clinical-stage biotechnology company pioneering peptide therapeutics for metabolic diseases, announced a major scientific breakthrough that could redefine the therapeutic landscape for general obesity treatment. The company's...Endevica Bio Announces First Patient Dosing in Phase 2 Trial in Patients with Stage 4 Metastatic Colorectal Cancer
NORTHBROOK, Ill., April 17, 2025 /PRNewswire/ -- Endevica Bio, a privately held company developing first-in-class peptide drug candidates, announced today the dose administration for the first patient in a Phase 2 trial for its experimental drug TCMCB07 (B07) to prevent weight loss in...Endevica Bio to Start Phase 2 Clinical Trial of Drug to Prevent Weight Loss in Cancer Patients
A peptide called TCMCB07 will be administered to patients who are diagnosed with stage 4 metastatic colorectal cancer and will undergo chemotherapy. NORTHBROOK, Ill., Dec. 20, 2024 /PRNewswire/ -- Endevica Bio, a privately held company developing first-in-class peptide drug candidates,...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Endevica Bio
Sign Up For FreeTo access detailed company insights
Endevica Bio specializes in novel peptidomimetics designed to treat conditions such as cancer cachexia and obesity with minimal side effects. Their innovative drug pipeline includes TCMCB07, currently in a Phase 2 trial for cancer cachexia, as well as 710GO, a weight loss medication showing effectiveness in non-human primates. The company is dedica... Read More
